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Digoxin is the most widely used cardiac glycoside for the
treatment of congestive heart failure and atrial fibrillation.
Digoxin is known to be converted metabolically to digoxi-
genin bis-digitoxoside, digoxigenin mono-digitoxoside and
digoxigenin by cleavage of the sugar moiety.1,2) In addition, it
is metabolized to dihydrodigoxin by reduction of the double
bond in the lactone ring.3)
The analysis of digoxin in biological fluids can be per-
formed by immunoassays. The antisera used for these im-
munoassays are produced by immunization with a hapten-
carrier protein conjugate, which is coupled to the terminal
digitoxose of digoxin using periodate oxidation.4,5) These an-
tisera show high cross-reactivity with metabolites formed by
the successive cleavage of the digitoxose residues.6—8)
In the radioimmunoassay (RIA) for determining digoxin
concentrations in serum, 3H- and 125I-labeled digoxin deriva-
tives have been widely used.8—10) We recently reported the
preparation and antigenic properties of digoxin–bovine
serum albumin (BSA) conjugates linked at the digitoxose C-
39 and C-30 positions.11,12) The properties of the antisera were
characterized by RIA for [3H]-digoxin. Although the anti-
serum elicited by digoxin 39-hemisuccinate–BSA conjugate
possesses high specificity for digoxin, it still lacks the sensi-
tivity needed for measurement of digoxin concentrations in
serum. The sensitivity of RIA increases using a tracer whose
specific radioactivity is high. In the present study, we de-
scribe development of a type of RIA of digoxin 39-hemisuc-
cinyl-[3H]leucine using the antiserum elicited by digoxin 
39-hemisuccinate–BSA conjugate for measuring digoxin in
serum from digitalized patients, and compare its perfor-
mance with commercially available anti-digoxin BSA serum
and monoclonal anti-digoxin.
MATERIALS AND METHODS
Materials L-[3,4,5-3H(N)]-Leucine (5328.0 GBq/mmol)
was supplied by New England Nuclear (Boston, MA,
U.S.A.). Dihydrodigoxin was obtained from Boehringer
Mannheim (Mannheim, Germany), Atomlight from Packard
BioScience B. V. (Groningen, The Netherlands), and BSA
(fraction V) from Sigma Chemical Co. (St. Louis, MO,
U.S.A.). Digoxin was purchased from Aldrich (Milwaukee,
WI, U.S.A.), Amberlite XAD-2 resin from Rohm and Haas
Co. (Philadelphia, PA, U.S.A.), and Dextran T-70 from Phar-
macia Fine Chemicals (Uppsala, Sweden). Norit SX and
other general reagents were supplied by Wako Pure Chemical
Industries (Osaka, Japan). Digoxigenin, and its mono- and
bis-digitoxosides were prepared by hydrolysis of digoxin ac-
cording to the methods of Kaiser and his colleagues.13)
RIA was performed in phosphate saline buffer (pH 7.4)
containing K2HPO4 (0.696 g), NaH2PO4·H2O (0.138 g),
NaCl (4.39 g), and BSA (1.0 g) in H2O (500 ml). A dextran-
coated charcoal suspension was prepared by continuously
stirring Norit SX (500 mg) and Dextran T-70 (50 mg) in cold
phosphate saline buffer (40 ml) for 10 min prior to use.
The antiserum (antibody (A)) was prepared by immuniz-
ing rabbit with digoxin 39-hemisuccinate–BSA conjugate.12)
The commercial anti-digoxin BSA serum (antibody (B)) and
monoclonal anti-digoxin (antibody (C)) were supplied by
BioMakor Co. (Rehovot, Israel).
Apparatus The melting point was determined with a
Yanagimoto micro hot-stage apparatus and is uncorrected.
Optical rotation was measured with a JASCO DIP-370 digi-
tal polarimeter. FAB-MS measurement was made on a JEOL
HX-100 instrument equipped with a FAB ion source using
glycerol and NaCl as the matrix agents. The UV spectrum
was obtained with a Shimadzu UV-3000 recording spec-
trophotometer. 1H-NMR spectra were recorded using tetra-
methylsilane as an internal standard for a JEOL GSX-400
spectrometer at 400 MHz. Abbreviations used: s5singlet,
d5doublet, and m5multiplet.
Digoxin 39-Hemisuccinylleucine (4) Digoxin 39-hemi-
succinate p-nitrophenyl ester (3) was prepared from digoxin
39-hemisuccinate (2).12) A solution of L-leucine (55 mg,
0.42 mmol) in H2O (10 ml) was added to a solution of 3
(115 mg, 0.11 mmol) in pyridine (10 ml), and the mixture
was stirred at room temperature for 18 h. The solution was
extracted with AcOEt, and the aqueous layer was percolated
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There is an antiserum elicited by digoxin 39-hemisuccinate–bovine serum albumin (BSA) conjugate possess-
ing high specificity for digoxin. Our study focused on development of RIA using this novel antiserum for mea-
surement of digoxin in serum from digitalized patients. The property of the new antiserum was investigated by
RIA with digoxin 39-hemisuccinyl-[3H]leucine. The separation of bound and free fractions was performed using a
dextran-coated charcoal suspension. The new antiserum bound approximately 50% of digoxin 39-hemisuccinyl-
[3H]leucine with a final dilution of 1 : 30000. The intra- and inter-assay coefficients of variation were ,9% in the
range of 0.52—4.17 ng/ml. The mean digoxin concentration in serum samples (n535) from digitalized patients
was estimated to be 0.68 ng/ml, which was lower than its measurement of digoxin with the commercial anti-
digoxin BSA serum and monoclonal anti-digoxin. It is apparent that the RIA described here has sufficient preci-
sion. The RIA system was available for the measurement of digoxin in serum from digitalized patients.
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through an Amberlite XAD-2 column (4731.5 cm i.d.). The
column was washed with H2O, then the desired compound
was eluted with MeOH. After evaporation of the MeOH frac-
tion, the crude product obtained was submitted to silica-gel
column (3731.0 cm i.d.) chromatography using CHCl3–
MeOH–H2O (80 : 20 : 2.5, v/v/v) as a mobile phase and 
further purified on a Sephadex LH-20 column (8131.5 cm
i.d.) using MeOH as an eluent. The eluate was recrystallized
from acetone–hexane to give 4 (37 mg, 34%) as a colorless
amorphous solid. mp 175—178 °C. [a]23D 133.0° (c50.21,
MeOH). Anal. Calcd for C51H79NO18· 2H2O: C, 59.46; H,
8.12; N, 1.36. Found: C, 59.48; H, 7.96; N, 1.38. FAB-MS
m/z: 1016 [M1Na]1. UV lmax (MeOH) nm (e): 215 (16000).
1H-NMR (CD3OD) d : 0.78 (3H, s, 18-CH3), 0.90—0.99 (9H,
m, 19- and leucine–CH3), 1.13—1.26 (9H, unresolved d, dig-
itoxose–CH3), 2.61 (4H, s, –CO(CH2)2CO–), 4.94 (2H, m,
21-CH2), 5.32 (1H, m, 39-H), 5.91 (1H, s, 22-H).
Digoxin 39-Hemisuccinyl-[3H]Leucine (5) A solution
of [3H]leucine (1.0 mCi) in EtOH–H2O (2 : 98, v/v) (1.0 ml)
was added to a solution of 3 (7.0 mg) in pyridine (1.0 ml),
and the mixture was stirred at room temperature for 19 h.
After addition of H2O (18 ml), the reaction mixture was
passed through the Sep-Pak C18 cartridge (weight of packed
material, 360 mg/cartridge). After washing with 30% MeOH
(50 ml), MeOH (5 ml) was passed through the cartridge. The
MeOH fraction was evaporated and dissolved in CHCl3–
MeOH–H2O (90 : 10 : 0.8, v/v/v) (2 ml), and loaded on the
Sep-Pak silica cartridge (weight of packed material, 690
mg/cartridge). After washing with CHCl3–MeOH–H2O (90 :
10 : 0.8, v/v/v) (48 ml), 5 was eluted with CHCl3–
MeOH–H2O (85 : 15 : 1, v/v/v) (20 ml). This clean-up proce-
dure with a Sep-Pak silica cartridge was repeated 3 times 
and the resulting labeled compound was stored in MeOH at
218 °C.
RIA Procedure For the digoxin free serum sample pool
serum from healthy volunteers who had not taken any drug
was used. The digoxin free serum (0.2 ml), digoxin 39-
hemisuccinyl-[3H]leucine (ca. 10000 dpm) diluted with the
assay buffer (0.1 ml), and diluted antiserum (0.3 ml) were
added to tubes containing from 0 to 15.65 ng/ml of non-la-
beled digoxin in assay buffer (0.1 ml). All tubes were shaken
in a vortex mixer and incubated at 4 °C for 3 h. A dextran-
coated charcoal suspension (0.3 ml) was added to each tube,
which was then vortexed, incubated for 10 min in an ice bath
and centrifuged at 17003g for 10 min at 4 °C. The super-
natant (0.7 ml) was transferred to a counting vial, scintilla-
tion solution (Atomlight, 6 ml) was added, and the radioac-
tivity was counted in an Aloka LSC-3000 liquid scintillation
counter. The radioactivity of the bound antibody was calcu-
lated after correction for the blank value (assay buffer). The
dose-response curve was constructed using duplicate sam-
ples.
Intra- and Inter-Assay Precision The intra- and inter-
assay precision using antibody (A) was assessed using the
digoxin free serum samples to which were added from 0.52
to 4.17 ng/ml of digoxin.
Cross-Reaction Study The specificities of antibodies
(A), (B), and (C) were tested by calculating the percentage of
cross-reactivity with various compounds.14) Cross-reactivity
was determined by the abovementioned assay procedure, by
comparing the concentrations of non-labeled digoxin and test
compounds necessary for a 50% displacement of the anti-
body-bound labeled digoxin.
Interference of Digoxin Metabolites with the Assay A
mixture of digoxin and its metabolites was prepared as fol-
lows: digoxigenin, its mono- and bis-digitoxoside each with
digoxin concentration of 10% were added to digoxin solu-
tions of 0.5, 1, and 2 ng/ml. This mixture was added to the
digoxin free serum samples and digoxin concentration was
analyzed by RIA using antibody (A), (B), or (C).
Determination of Digoxin in Serum from Digitalized
Patients The patient serum samples were obtained during
routine monitoring of serum digoxin concentrations or other
laboratory tests of digitalized patients in Saiseikai Kanazawa
Hospital. The samples were stored at 218 °C until assayed.
Patient serum sample (0.2 ml), assay buffer (0.1 ml), digoxin
39-hemisuccinyl-[3H]leucine (0.1 ml), and diluted antiserum
(0.3 ml) were added to test tubes. Digoxin concentration in
the sample of 0.2 ml was determined by RIA as described
above.
RESULTS AND DISCUSSION
The radiochemical purity of digoxin 39-hemisuccinyl-
[3H]leucine was checked by TLC. TLC separation and the
radio-chromatogram are shown in Fig. 1. Digoxin 39-
hemisuccinylleucine (4) used as a standard was prepared
from digoxin 39-hemisuccinate p-nitrophenyl ester (3), which
was derived from 2 (Chart 1). The Rf values of L-leucine,
digoxin 39-hemisuccinylleucine, and digoxin 39-hemisucci-
nate were 0.18, 0.35, and 0.47, respectively. Also, the ra-
dioactivity of digoxin 39-hemisuccinyl-[3H]leucine correlated
well with the Rf value of digoxin 39-hemisuccinylleucine.
The properties of antibodies (A), (B), and (C) were inves-
tigated by RIA with digoxin 39-hemisuccinyl-[3H]leucine.
The separation of bound and free fractions was performed
using a dextran-coated charcoal suspension. Antibodies (A),
(B), and (C) bound approximately 50% of digoxin 39-
hemisuccinyl-[3H]leucine with a final dilution of 1 : 30000,
1 : 46000, and 1 : 160000, respectively. The association con-
stants of these antibodies were determined to be 1.83109,
2.731010, and 8.431010 M21 from a Scatchard plot.15) The
standard curves obtained with antibodies (A), (B), and (C)
are presented in Fig. 2. The plot of percent bound radioactiv-
ity vs. logarithm of the amount of non-labeled digoxin
showed a linear relationship over the range of 0.03 to 1.5 ng
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Fig. 1. Thin-Layer Chromatogram (Below) and Radio-Chromatogram
(Above) of Labeled Digoxin
TLC specifications: plate, Merck silica-gel 60 F254; developing solvent,
CHCl3–MeOH–H2O (75 : 25 : 3.5, v/v/v). Visualization: spraying with ninhydrin and
concentrated sulfuric acid followed by heating in an oven at 120 °C for 10 min. A, L-
leucine; B, digoxin 39-hemisuccinylleucine; and digoxin 39-hemisuccinyl-[3H]leucine;
C, digoxin 39-hemisuccinate.
for antibodies (A) and (C), while the plot was linear over the
range of 0.02 to 0.7 ng for antibody (B).
The precision of RIA using antibody (A) was evaluated.
The intra-, inter-assay, and recovery are presented in Table 1.
The intra-assay coefficients of variation (CV) were 2.8—
6.3% (n58); the inter-assay CV was 7.1—8.3% (n58). The
recovery of various amounts of digoxin added to the digoxin
free serum was satisfactory.
The specificities of antibodies (A), (B), and (C) were as-
sessed by cross-reaction tests with various related com-
pounds. Percentages indicating cross-reactivities at 50% dis-
placement of the antibody-bound digoxin 39-hemisuccinyl-
[3H]leucine compared to digoxin were calculated and the 
results are listed in Table 2. Antibody (A) possessed high
specificity, exhibiting minor cross-reactions with dihydro-
digoxin (9.4%), and digitoxin (6.1%). Also, there were no
significant cross-reactions with digoxigenin bisdigitoxoside
(0.34%), digoxigenin monodigitoxoside (0.11%), or digoxi-
genin (0.02%). All other compounds tested showed negligi-
ble values of ,0.01%. In contrast, antibodies (B) and (C)
showed high cross-reactivity to digoxin degradation prod-
ucts. Antibody (A) is highly specific for both the digitoxose
chain and the steroid portion of the molecule. However, anti-
bodies (B) and (C) were inferior in terms of specificity with
respect to changes in the digitoxose part or the steroid moi-
ety of digoxin.
A mixture of digoxin, digoxigenin bisdigitoxoside, digoxi-
genin monodigitoxoside and digoxigenin was added to the
digoxin free serum and digoxin concentration was analyzed
by RIA using antibody (A), (B), or (C). Recoveries for
digoxin by antibodies (A), (B), and (C) were 100.0—
101.5%, 122.0—144.0%, and 121.5—154.0%, respectively
(Table 3). Antibody (A) recovers digoxin closest to the origi-
nal analyte spike level, but antibodies (B) and (C) recover
much higher digoxin than the digoxin spike level; this may
be due to the high cross-reactivity of these two antibodies
with the digoxin metabolites present in the mixtures.
The serum samples (n535) obtained from digitalized pa-
tients were measured by RIA using antibody (A) and its per-
formance was compared with RIAs using antibodies (B) and
(C), respectively (Fig. 3). When antibody (A) was used, the
mean digoxin concentration was 0.68 ng/ml (range, 0.24—
1.50 ng/ml). Then, the same samples were measured with 
antibodies (B) and (C), and the mean values of digoxin were
0.79 ng/ml (range, 0.34—1.79 ng/ml) and 0.80 ng/ml (range,
0.32—1.85 ng/ml), respectively. We suggest that the digoxin
measurement results detailed with antibody (A) are accurate.
On the other hand, the values obtained using antibodies (B)
and (C) were higher than that of antibody (A). It is possible
that the RIA using antibodies (B) and (C) measures not only
digoxin but also its metabolites. We surmised from the dis-
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Table 1. Precision of the RIA System Using Antibody (A)
Added 
Intra-assay (n58) Inter-assay (n58)
(ng/ml)
Mean (ng/ml) S.D. (ng/ml) CV (%) Recovery (%) Mean (ng/ml) S.D. (ng/ml) CV (%) Recovery (%)
0.52 0.48 0.03 6.3 92.3 0.60 0.05 8.3 115.4
1.05 1.08 0.06 5.6 102.9 1.10 0.09 8.2 104.8
2.09 2.21 0.08 3.6 105.7 2.16 0.16 7.4 103.3
4.17 4.29 0.12 2.8 102.9 4.23 0.30 7.1 101.4
Table 2. Cross-Reaction Data of Anti-digoxin Antibody
Compound
% Cross-reactivity (50%)a)
Antibody (A) Antibody (B) Antibody (C)
Digoxin 100 100 100
Digoxigenin 0.34 111 91.9
bisdigitoxoside
Digoxigenin 0.11 122 120
monodigitoxoside
Digoxigenin 0.02 82.2 106
Dihydrodigoxin 9.4 0.8 4.3
Digitoxin 6.1 0.6 8.7
Spironolactone ,0.01 ,0.01 ,0.01
Digitoxose ,0.01 ,0.01 ,0.01
Progesterone ,0.01 ,0.01 ,0.01
Testosterone ,0.01 ,0.01 ,0.01
Choresterol ,0.001 ,0.001 ,0.001
a) Values are calculated on a molar basis.
Chart 1
Fig. 2. Standard Curves for Digoxin Using Anti-digoxin Antibodies
Antibodies (A) (d), (B) (s), and (C) (m).
persion of measured value that individual differences be-
tween patients exist with regard to rate of metabolism from
digoxin to digoxigenin, its mono- and bis-digitoxoside, and
dihydrodigoxin.
Immunoassays are typically used for therapeutic drug
monitoring of the cardiac glycosides, and in these im-
munoassays, antibody with cross-reactivity to metabolites of
this drug matching the drug’s biological activities should be
used.7,8,16—18) It should be mentioned that the RIA developed
here does not meet this requirement. However, this RIA
using antibody (A) measures unmetabolized digoxin, and
may be utilized for pharmacokinetics studies. Antibody (A)
may also be useful for therapeutic immunoextraction of
digoxin in patients with digoxin overdoses.
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Table 3. Interference of Digoxin Metabolites on the Assay
Antibody (A) Antibody (B) Antibody (C)
Added
Mean6S.D. (ng/ml) Recovery (%) Mean6S.D. (ng/ml) Recovery (%) Mean6S.D. (ng/ml) Recovery (%)
(n55) (n55) (n55)
Digoxin (0.5 ng/ml)1
each metabolite (0.05 ng/ml) 0.5060.10 100.0 0.7260.03 144.0 0.7760.05 154.0
Digoxin (1 ng/ml)1
each metabolite (0.1 ng/ml) 1.0060.06 100.0 1.2260.05 122.0 1.2360.03 123.0
Digoxin (2 ng/ml)1
each metabolite (0.2 ng/ml) 2.0360.06 101.5 2.4760.10 123.5 2.4360.08 121.5
Metabolites are digoxigenin, digoxigenin monodigitoxoside, and digoxigenin bisdigitoxoside.
Fig. 3. Plots of Values Assaying Serum Samples of Digitalized Patients
(A) A comparison of antibody (A) and (B). (B) A comparison of antibody (A) and
(C).
